Evidence map›Paper›PMID 36653019›Full record

ArticleEnvironmental science & technology2023

Minimizing Experimental Testing on Fish for Legacy Pharmaceuticals.

Anja Coors, A Ross Brown, Samuel K Maynard, Alison Nimrod Perkins, Stewart Owen, Charles R Tyler

Abstract read
In one paragraph

Article in Environmental science & technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Environmental science & technology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anja CoorsECT Oekotoxikologie GmbH, Böttgerstraße 2-14, 65439 Flörsheim/Main, Germany.ORCID 0000-0002-9224-2917
A Ross BrownBiosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, Devon, U.K.ORCID 0000-0002-3892-8993
Samuel K MaynardGlobal Sustainability, AstraZeneca, Eastbrook House, Shaftesbury Road, Cambridge CB2 8DU, U.K.
Alison Nimrod PerkinsEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States.
Stewart OwenGlobal Sustainability, AstraZeneca, Eastbrook House, Shaftesbury Road, Cambridge CB2 8DU, U.K.
Charles R TylerBiosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, Devon, U.K.

Funding

Medical Research Council MC_PC_17189National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/R001421/1
6 · The paper itself

Abstract

There was no regulatory requirement for ecotoxicological testing of human pharmaceuticals authorized before 2006, and many of these have little or no data available to assess their environmental risk. Motivated by animal welfare considerations, we developed a decision tree to minimize in vivo fish testing for such legacy active pharmaceutical ingredients (APIs). The minimum no observed effect concentration (NOEC

Indexed as

FishesPharmaceutical PreparationsWater Pollutants, ChemicalAnimalsDaphniaEcotoxicologyEnvironmental MonitoringRisk AssessmentPharmaceutical PreparationsWater Pollutants, Chemicalanimal welfareecotoxicityenvironmental risk assessmentfish plasma modelvertebrate testing

Identifiers

PMID36653019
PMCPMC9893720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.